A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders.
Epistemonikos ID: b1de6adba5e15842e14771e4fe8d291bbec503bd
First added on: May 06, 2024